Allakos Inc.
Allakos Inc. (ALLK): 4 pipeline candidates · ~6 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.8 months
D/E 0.07 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for Allakos Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$24.2M
Quarterly Burn
$28.4M
Runway
5.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Allakos Inc.'s pipeline?
Allakos Inc. (ALLK) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Allakos Inc.'s lead drug candidate?
Allakos Inc.'s most advanced tracked candidate is ak006 (Phase 1) for Chronic spontaneous urticaria (CSU).
What is Allakos Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Allakos Inc. has approximately 5.8 months of cash runway.
Who is the CEO of Allakos Inc.?
Robert Alexander, Ph.D. is the chief executive officer of Allakos Inc. (ALLK).
Get the full picture on Allakos Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.